Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
About Artivion, Inc. (NYSE: AORT)
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a prominent medical device company dedicated to developing elegant and straightforward solutions addressing the complex challenges faced by cardiac and vascular surgeons in treating aortic diseases. The company offers a wide array of aortic-centric products, including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, distributed in over 100 countries worldwide.
Recent Achievements and Financial Performance:
- For the third quarter of 2023, Artivion reported revenues of $87.9 million, marking a 14% increase year-over-year, with notable growth in aortic stent grafts and On-X mechanical heart valves.
- Completed enrollment in the PERSEVERE clinical trial, targeting PMA approval for the AMDS Hybrid Prosthesis by 2025, showcasing significant reductions in all-cause mortality and major adverse events.
- Announced a comprehensive $350 million non-dilutive credit agreement to address debt maturities and further optimize the capital structure, highlighting the company's strategic growth initiatives.
Product Innovation and Clinical Trials:
- The On-X Aortic Heart Valve Low INR post-market study demonstrated superior patient outcomes, significantly reducing major bleeding events compared to historic controls.
- Artivion's product portfolio includes innovative solutions like the AMDS Hybrid Prosthesis, aimed at improving outcomes for patients with acute DeBakey Type I aortic dissections.
With a strong focus on clinical efficacy and market expansion, Artivion continues to be a pivotal player in the cardiac and vascular surgery market, striving to deliver life-saving products and technologies that improve patient outcomes.
Artivion, Inc. (NYSE: AORT) announced the appointment of Elizabeth A. Hoff to its Board of Directors, effective October 1, 2022. Hoff brings over 30 years of experience in the medical device industry, including senior roles in the aortic space. Her expertise will support Artivion's strategic growth initiatives and strengthen its market position in treating aortic diseases. Chairman and CEO Pat Mackin expressed enthusiasm for Hoff's inclusion, expecting her leadership to drive innovation and progress within the company.
Artivion, Inc. (AORT) announced the termination of the PROACT Xa clinical trial on September 23, 2022. The independent Data and Safety Monitoring Board recommended stopping the trial due to insufficient evidence supporting the non-inferiority of apixaban compared to warfarin for patients with On-X mechanical aortic valves. The trial, which began in April 2020, showed a higher incidence of blood clots and stroke in apixaban patients. Despite this setback, Artivion reiterated its commitment to double-digit growth and plans to redirect the previously allocated $10 million funding towards enhancing EBITDA and cash flow.
Artivion, Inc. (NYSE: AORT), a prominent company in cardiac and vascular surgery focused on aortic disease, announced it will present at the Deutsche Bank 30th Annual Leveraged Finance Conference on September 21, 2022, at 9:20 a.m. MST. The presentation will be available via a live webcast on the company's website, with an archived version accessible for 90 days. Artivion specializes in developing solutions for aortic diseases, marketing products in over 100 countries. For further details, visit www.artivion.com.
Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery, announced its participation in two investor conferences. The first is the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, where a live webcast of the presentation will start at 4:05 p.m. ET. The second is the Lake Street 6th Annual Best Ideas Growth Conference on September 14, 2022, with no webcast available. Artivion focuses on developing solutions for aortic diseases and offers products like aortic stent grafts and On-X mechanical heart valves.
Artivion, Inc. (NYSE: AORT), a company specializing in cardiac and vascular solutions for aortic disease, will present at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 1:30 p.m. ET. The presentation will be available through a live webcast on Artivion's website, with an archived version accessible for 90 days post-event. Artivion offers diverse products including aortic stent grafts and On-X mechanical heart valves, serving over 100 countries globally.
Artivion reported a revenue of $80.3 million for Q2 2022, marking a 6% increase year-over-year on a GAAP basis and 9% increase on a non-GAAP constant currency basis. Aortic stent graft revenue grew 23%, while On-X revenue rose 12%. The company faced a net loss of ($4.3 million), compared to a loss of ($2.2 million) in Q2 2021. Artivion anticipates 9% to 11% constant currency revenue growth for the full year 2022.
Artivion, Inc. (NYSE: AORT) has announced its participation in two upcoming investor conferences. The management team will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 9:30 a.m. ET in Boston, with a live webcast available on the company’s website. Additionally, they will participate in the Needham Virtual Med Tech & Diagnostics 1x1 Conference on August 15-16, 2022, with no webcast available. Artivion focuses on innovative solutions for aortic disease and markets products in over 100 countries.
Artivion (NYSE: AORT) has initiated the PERSEVERE clinical trial to evaluate the safety and efficacy of the AMDS Hybrid Prosthesis for treating acute DeBakey Type I aortic dissections. The trial aims to enroll approximately 100 participants across the U.S. and support the FDA's premarket approval application. Successful trial results could lead to the AMDS' approval by late 2024 or early 2025. The AMDS is designed to improve patient outcomes significantly, addressing high mortality rates associated with this condition.
Artivion, Inc. (NYSE: AORT) announced the release date for its second quarter 2022 financial results, set for August 4, 2022, after market close. A teleconference will follow at 4:30 p.m. ET, hosted by Pat Mackin, CEO. Investors can access the live webcast through Artivion's website and a replay will be available shortly after the call. Artivion specializes in solutions for aortic diseases and markets its products in over 100 countries. For more details, visit www.artivion.com.
Artivion, Inc. (NYSE: AORT) has announced its participation in the UBS 2022 Global Healthcare Conference on May 23, 2022, at the Lotte New York Palace, with a fireside chat scheduled for 2:45 p.m. ET. A live webcast will be accessible through Artivion's website, and an archived version will be available for 90 days. Based in Atlanta, Georgia, Artivion develops solutions for cardiac and vascular surgeons treating aortic diseases, offering products like aortic stent grafts and On-X mechanical heart valves.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
What products does Artivion, Inc. offer?
Where is Artivion, Inc. headquartered?
What are some recent clinical achievements of Artivion?
What was Artivion's revenue growth in the third quarter of 2023?
How is Artivion addressing its debt maturities?
In how many countries does Artivion market its products?
What is the focus of Artivion's clinical trials?
What are the key products in Artivion's portfolio?
What are the benefits of the On-X Aortic Heart Valve?
When does Artivion expect to achieve PMA approval for the AMDS Hybrid Prosthesis?
